Expert Interview
Investigating the potential of liraglutide, a GLP-1 agonist from Novo Nordisk as a preventative treatment of Alzheimer's disease.
Ticker(s): NVOInstitution: Zucker Hillside Hospital
- Chief of Neurology at Zucker Hillside Hospital
- Professor of neurology and psychiatry at Donald and Barbara Zucker School of Medicine
- Manages 150 patients with Alzheimer's Disease
- Has been a Principal Investigator in clinical research studies of Alzheimer’s disease, mild cognitive impairment, and vascular dementia.
Can you provide some background information about yourself, your expertise, and your current practice setting?
How many Alzheimer's patients do you currently see on a monthly basis, and what is your treatment algorithm for Alzheimer's disease?
What are your thoughts on the differences between Leqembi and Kisunla, and which one do you think might be preferable?
What is your opinion on the potential of the GLP-1 class, particularly liraglutide, for the treatment of Alzheimer's disease, and do you see differences between liraglutide, semaglutide, and tirzepatide?
How do you see GLP-1 agonists fitting into your treatment algorithm if approved for Alzheimer's disease, and what is your level of excitement for this class as a potential treatment?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
